Polymyalgia rheumatica - Revision history

Danbot: Add MedicationDose entry (prednisone) with SMW annotations

2026-03-20T19:02:05Z

Add MedicationDose entry (prednisone) with SMW annotations

@@ Line 29: / Line 29: @@
 ==Disposition==
 *Discharge
 ==See Also==

Rossdonaldson1: /* Management */

2023-09-13T20:35:52Z

Management

← Older revision		Revision as of 20:35, 13 September 2023
Line 22:		Line 22:
	==Management==		==Management==
	*Low-dose [[Corticosteroids]] typically produce rapid response<ref>https://emedicine.medscape.com/article/330815-overview</ref>		*Low-dose [[Corticosteroids]] typically produce rapid response<ref>https://emedicine.medscape.com/article/330815-overview</ref>
	**Example regimen ~~is prednisone~~ 15 mg PO QD for 2-4 weeks. Needs to start a year-long taper after the first month, so write enough for them to get in with PCP.		**Example regimen:
			***[[Prednisone]] 15 mg PO QD for 2-4 weeks
			***Needs to start a year-long taper after the first month, so write enough for them to get in with PCP.
	*Avoid [[NSAIDs]] if history of or concern for [[GCA]] due to risk of renal injury		*Avoid [[NSAIDs]] if history of or concern for [[GCA]] due to risk of renal injury

Urinetrouble: Added basic regimen

2023-09-08T19:01:41Z

Added basic regimen

← Older revision		Revision as of 19:01, 8 September 2023
Line 22:		Line 22:
	==Management==		==Management==
	*Low-dose [[Corticosteroids]] typically produce rapid response<ref>https://emedicine.medscape.com/article/330815-overview</ref>		*Low-dose [[Corticosteroids]] typically produce rapid response<ref>https://emedicine.medscape.com/article/330815-overview</ref>
			**Example regimen is prednisone 15 mg PO QD for 2-4 weeks. Needs to start a year-long taper after the first month, so write enough for them to get in with PCP.
	*Avoid [[NSAIDs]] if history of or concern for [[GCA]] due to risk of renal injury		*Avoid [[NSAIDs]] if history of or concern for [[GCA]] due to risk of renal injury

Kennybroccoli: /* Background */

2022-12-16T00:03:30Z

Background

← Older revision		Revision as of 00:03, 16 December 2022
Line 2:		Line 2:
	*Chronic inflammatory condition		*Chronic inflammatory condition
	*Primarily affects elderly		*Primarily affects elderly
			**Almost exclusively in those over the age of 50, peak incidence occurs between ages 70-80<ref>Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970-1991. Arthritis Rheum. 1995 Mar;38(3):369-73. doi: 10.1002/art.1780380311. PMID: 7880191.</ref>

	==Clinical Features==		==Clinical Features==

Kennybroccoli: /* Clinical Features */

2022-12-16T00:02:43Z

Clinical Features

← Older revision		Revision as of 00:02, 16 December 2022
Line 6:		Line 6:
	==Clinical Features==		==Clinical Features==
	*Onset abrupt or subacute (weeks-months)		*Onset abrupt or subacute (weeks-months)
	*Proximal [[myalgia]] primarily ~~of hip~~ and ~~shoulder girdles~~		*Proximal [[myalgia]] primarily involving hips, shoulders, and neck
	*Morning stiffness		*Morning stiffness
	*[[Giant cell arteritis]] develops in approximately 15% of patients with PMR<ref>Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology (Oxford). 2017 Apr 1. 56 (4):506-515</ref>		*[[Giant cell arteritis]] develops in approximately 15% of patients with PMR<ref>Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology (Oxford). 2017 Apr 1. 56 (4):506-515</ref>
	*+/- constitutional symptoms (fatigue/malaise, low-grade [[fever]], anorexia)		*+/- constitutional symptoms (fatigue/malaise, low-grade [[fever]], anorexia)
	*+/- [[anemia		*+/- [[anemia]]
	*[[Rheumatoid arthritis]]-like symptoms (joint pain/swelling, degenerative changes) in 30% of patients<ref>https://rarediseases.org/rare-diseases/polymyalgia-rheumatica/</ref>		*[[Rheumatoid arthritis]]-like symptoms (joint pain/swelling, degenerative changes) in 30% of patients<ref>https://rarediseases.org/rare-diseases/polymyalgia-rheumatica/</ref>

ClaireLewis: Created page with "==Background== Chronic inflammatory condition Primarily affects elderly ==Clinical Features== Onset abrupt or subacute (weeks-months) Proximal myalgia primarily of h..."

2019-08-18T15:13:01Z

Created page with "==Background== *Chronic inflammatory condition *Primarily affects elderly ==Clinical Features== *Onset abrupt or subacute (weeks-months) *Proximal myalgia primarily of h..."

New page

==Background==
*Chronic inflammatory condition
*Primarily affects elderly

==Clinical Features==
*Onset abrupt or subacute (weeks-months)
*Proximal [[myalgia]] primarily of hip and shoulder girdles
*Morning stiffness
*[[Giant cell arteritis]] develops in approximately 15% of patients with PMR<ref>Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology (Oxford). 2017 Apr 1. 56 (4):506-515</ref>
*+/- constitutional symptoms (fatigue/malaise, low-grade [[fever]], anorexia)
*+/- [[anemia
*[[Rheumatoid arthritis]]-like symptoms (joint pain/swelling, degenerative changes) in 30% of patients<ref>https://rarediseases.org/rare-diseases/polymyalgia-rheumatica/</ref>

==Differential Diagnosis==
{{Myalgia DDX}}

==Evaluation==
*Clinical diagnosis
*Evaluate for alternate diagnoses

==Management==
*Low-dose [[Corticosteroids]] typically produce rapid response<ref>https://emedicine.medscape.com/article/330815-overview</ref>
*Avoid [[NSAIDs]] if history of or concern for [[GCA]] due to risk of renal injury

==Disposition==
*Discharge

==See Also==
*[[Giant cell arteritis]]

==External Links==

==References==
<references/>
[[Category:ID]]